Don J. Diamond, Ph.D.

Research Focus :
  • Cancer and Viral Vaccines

Don J. Diamond, Ph.D., chairs the Department of Experimental Therapeutics, which develops vaccines to combat hematologic malignancies, solid tumors, and infectious pathogens such as the herpesvirus, cytomegalovirus (CMV) HIV.

The prospect of an effective CMV vaccine means significant benefits for immunocompromised patients such as those with AIDS, or stem cell and solid organ transplant recipients.  A therapeutic CMV peptide vaccine developed in the department is undergoing phase II human efficacy testing in City of Hope stem cell transplant recipients, while a second generation CMV vaccine based on the attenuated poxvirus MVA, or modified vaccinia Ankara, is currently undergoing phase I human safety testing.

A vaccine developed in the department also based on the MVA platform expressing unmutated p53 has completed phase I human testing in City of Hope gastrointestinal cancer patients.  In the laboratory, we are refining a therapeutic platform based on attenuated Salmonella bacterium to treat a range of malignancies including pancreatic, skin and brain cancers.  In collaboration with Peter Barry, Ph.D., of University of California at Davis and the National Primate Research Center, we are developing a prophylactic CMV vaccine that promises to control gestational infection that causes a wide range of birth defects that annually afflict close to 4,000 American children.

  • 2014 - Present, Chair and Professor, Department of Experimental Therapeutics
  • 2013 - 2014, Associate Chair, Department of Virology
  • 2008 - 2014, Director, Division of Translational Vaccine Research, Beckman Research Institute of City of Hope, Duarte, CA
  • 1999 - 2014, Professor, Department of Virology, Beckman Research Institute
  • 1999 - 2008, Head, Laboratory of Vaccine Research, Department of Virology, Beckman Research Institute
  • 1994 - 1999, Associate Research Scientist, Hematology Research, City of Hope, Duarte, CA
  • 1989 - 1994, Assistant Research Scientist and Section Head, Department of Immunology, Beckman Research Institute of City of Hope, Duarte, CA
  • 1986 - 1989, Research Fellow and Instructor in Pathology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
  • 1985 - 1987, Leukemia Society of America Fellow with E. Reinherz, M.D., DFCI, Harvard Medical School, Boston, MA
  • 1984 - 1986, Postdoctoral Fellow with S. Tonegawa, Ph.D., Center for Cancer Research, MA, MIT, Cambridge, MA
  •     1984, Harvard Medical School, Boston, Massachusetts, Ph.D., Biological Chemistry
  •     1977, Harvard University, Cambridge, Massachusetts, A.B., Biology (Magna Cum Laude)

Project 1:  Phase 1b And Phase 2 Evaluation Of Protective Efficacy, Safety And Correlative Immunogenicity Studies Of Cmvpepvax Co-Injected With Pf03512676 Adjuvant In Recipients Of Allogeneic Stem Cell Transplant
Project 2:  Control Of Cmv Infection In Allogeneic Stem Cell Transplant Recipients Using Attenuated Mva-Based Cmv Subunit Vaccine
Project 3:  Phase I Study Of A P53-Mva Vaccine For Advanced Colon, Gastric And Pancreatic Cancer
Project 4:  Development Of Vaccine Strategies To Prevent Congenital Cytomegalovirus Infection
Project 5:  Ido-Silencing Salmonella Therapy For The Treatment Of Primary And Metastatic Pdac
Project 6:  Pilot Project - Blockade Of Immune Checkpoint Receptors For The Treatment Of Pancreatic Cancer

The Laboratory of Vaccine Research (LVR) was originally formed by  Don J. Diamond, Ph.D. in 2000 to address priorities in vaccine research that would potentially impact patient outcomes at the City of Hope (COH) and other cancer centers worldwide.  The LVR later evolved into the Division of Translational Vaccine Research (TVR) in 2008, which has, since then, focused on the clinical translation of vaccine and therapeutic strategies to combat herpes viral infections, hematologic malignancies, and solid tumors. Our comprehensive program has now developed molecular vaccines and therapies that incorporate various technologies such as peptides and viral or bacterial vectors to directly elicit, or encode antigens that elicit, viral- or cancer-specific immune responses. Currently, the TVR has produced several agents that have advanced beyond pre-clinical testing into Phase I and II trials. The mission of the TVR is to continue progress in the development and testing of treatments with clinical benefit for cancer patients.  In 2014, the TVR was transformed into the Department of Experimental Therapeutics (ET).  The mission of the ET department will encompass the work of the TVR and broaden its scope to include more basic studies in basic and tumor immunology.

Learn more.

Marcela D Alincourt Salazar, Ph.D
Staff Scientist
[email protected]

Supriya Bautista
Project Coordinator
[email protected]

Flavia Chiuppesi, Ph.D
Staff Scientist
[email protected]

Heidi Contreras, Ph.D.
Postdoctoral Fellow
[email protected]

Nicola Hardwick, Ph.D.
Regulatory Affairs Specialist
[email protected]

Angelina Iniguez
Research Associate II
[email protected]

Benjamin Johnson
Graduate Student II
[email protected]

Teodora Kaltcheva, Ph.D.
Staff Scientist
[email protected]

Ferdynand Kos, Ph.D.
Staff Scientist
[email protected]

Peter Kwon, M.P.A.
Business Manager
[email protected]

Melanie Lampa
Laboratory Manager
[email protected]

Chetan Raj Lingaraju
Research Associate II
[email protected]

Joybelle Martinez
Senior Research Associate
[email protected]

Aline Matsuo, Ph.D.
Senior Administrative Support
[email protected]

Zhuo Meng, M.D.
Research Assistant II
[email protected]

Jenny Nguyen, M.Sc.
Research Associate II
[email protected]

Vu Nguyen, Ph.D.
Postdoctoral Fellow
[email protected]

Soojin Park, Ph.D.
Postdoctoral Fellow
[email protected]

Charmaine Soco
Graduate Student
[email protected]

Weimin Tsai
Research Associate II
Department of Hematology
[email protected]

Qiao Zhou
Research Associate II
[email protected]

Vaccine Therapies for Cancer - Don J. Diamond, Ph.D.
Vaccine Therapies for Cancer - Don J. Diamond, Ph.D.

Vaccine Therapies for Cancer - Don J. Diamond, Ph.D.

August 11, 2015
  • Chiuppesi F, Wussow F, Scharf L, Gao H, Zhuo M, Bjorkman PJ, Diamond DJ. Comparison of homologous and heterologous prime boost immunization strategies against cytomegalovirus. In Preparation
  • Chiuppesi F, Wussow F, Kaltcheva T, Zhuo M, Diamond DJ. A cryptic epitope on human cytomegalovirus UL128 induces neutralizing antibodies in mice. In Preparation
  • Wussow F, Chiuppesi F, Martinez J, Zhuo M, Nguyen J, Diamond DJ. A Bacterial Artificial Chromosome Clone of MVA Allows Induction of Potent Neutralizing Antibodies Against Human Cytomegalovirus by a Self-cleaving Pentamer Complex. In Preparation
  • La Rosa C, Longmate J, Martinez J, Zhou Q, Kaltcheva T, Tsai W, Drake J, Carroll M, Wussow F, Chiuppesi F, Dadwal S, Aldoss I, Nakamura R, Zaia JA, Diamond DJ.  MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T-cells in healthy adults independent of CMV serostatus, Blood, Submitted 07/22/2016
  • Yue Y, Kaur A, Anders L, Diamond DJ, Walter MR, Barry PA. The Susceptibility of Primary Cultured Rhesus Macaque Kidney Epithelial Cells to Rhesus Cytomegalovirus Strains. Accepted, J Gen Virol. 01/2016 doi: 10.1099/jgv.0.000455
  • Salazar, M, Manuel ER, Tsai W, D'Apuzzo M, Goldstein L, Blazar R, Diamond DJ.  Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. OncoImmunology, 10.1080/2162402X.2016.1160184 Available online 03/16
  • Chen J, Diamond DJ, Manuel ER. Developing Effective Salmonella-based Approaches to Treat Pancreatic Cancer. Pancreat Disord Ther. 2016;6(1):1-2. PMC4764990
  • Nakamura R, La Rosa C, Longmate J, Drake J, Slape C, Zhou Q, Lampa MG, O’Donnell M, Cai J-L, Farol L, Salhotra A, Snyder DS, Aldoss I, Forman SJ, Miller JS, Zaia JA, Diamond DJ. Viraemia, immunogenicity, and survival outcomes of CMV  chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haematopoietic stem-cell transplantation: randomized phase 1b trial. The Lancet Haematology. 2016 Feb; 3(2):e87-98. doi: 10.1016/S2352-3026(15)00246-X.  PMC4926626
  • Limaye AP, La Rosa C Longmate J, Diamond DJ. Plasma IL-10 levels to guide antiviral prophylaxis prevention of late-onset CMV disease. Transplantation, 100(1):210-6, 1/2016. PMC4685744  
  • Cichocki F, Cooley S, Davis Z, DeFor TE, Schlums H, Zhang B, Brunstein CG, Blazar BR, Wagner J, Diamond DJ, Verneris MR, Bryceson YT, Weisdorf DJ, Miller JS. CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia. doi:10.1038/leu.2015.260 09/2015. PM: PMC4740203
  • Bialas KM, Tanaka T, Tran D, Varner V, Cisneros E, Chiuppesi F, Wussow F, Kattenhorn L, Macri S, Kunz EL, Estroff JA, Kirchherr J, Yue Y, Fan Q, Lauck M, O’Connor DH, Hall AHS, Xavier A, Diamond DJ, Barry PA, Kaur A, Permar S.  Maternal CD4+ T cells protect against severe congenital CMV disease in a novel nonhuman primate model of placental CMV transmission. P Natl Acad Sci, 112(44):13645-50, 2015. PMC4640765
  • Chiuppesi F, Wussow F, Johnson E, Bian C, Zhuo M, Rajakumar A, Barry PA, Britt WJ, Chakraborty R, Diamond DJ. Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Complex Neutralize Infection of Primary Cytotrophoblasts. J Virol. 89(23):1184-11898, 2015. PMC4645301
  • Manuel ER, Chen J, D’Apuzzo M, Lampa MG, Kaltcheva TI, Thompson CB, Ludwig T, Chung V, Diamond DJ. Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. Cancer Immunol Res. 3(9):1096-1107, 2015. PMC4561205
  • Swanson ED, Gillis P, Hernandez-Alvarado N, Fernández-Alarcón C, Schmit M, Zabeli JC, Wussow F, Diamond DJ, and Schleiss MR. Comparison of Monovalent Glycoprotein B with Bivalent gB/pp65 (GP83) Vaccine for Congenital Cytomegalovirus Infection in a Guinea Pig Model: Inclusion of GP83 Reduces Antibody Response but Provides Equivalent Protection Against Mortality. Vaccine. 33(32):4013-8, 2015. PMC4772145
  • Davis Z, Cooley S, Cichocki F, Felices M, Wangen R, Luo X, DeFor TE Bryceson YT, Diamond DJ, Brunstein C, Blazar BR, Wagner JE, Weisdorf DJ, Horowitz A, Guethlein LA, Parham P, Verneris MR,  Miller JS. Adaptive NK cell and KIR-expressing T cell responses are induced by CMV and are associated with protection against CMV reactivation after allogeneic donor hematopoietic cell transplantation. Biol Blood Marrow Tr. 21(9):1653-62, 2015. PMC4557961
  • Wang X, Wong CW, Urak R, Mardiros A, Budde LE, Chang W-C, Thomas SH, Brown CE, La Rosa C, Diamond DJ, Jensen MC, Nakamura R, Zaia JA, Forman SJ. CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells. Clin Cancer Res. 21(13):2993-3002, 2015. PMC4489991
  • Weiman S (main author), Diamond DJ (co-author), et al.  Harnessing the Power of Microbes as Therapeutics: Bugs as Drugs.  American Academy of Microbiology Colloquium report.  Copyright 2015.
  • Gibson L, Barysauskas CM, McManus M, Dooley S, Lilleri D, Fisher D, Srivastava T, Diamond DJ, Luzuriaga K. Reduced frequencies of polyfunctional CMV-specific T cell responses in infants with congenital CMV infection. J Clin Immunol,  35(3):289-301, 2015. PMC4366322
  • Israyelyan A, Goldstein L, Tsai W, Aquino L, Forman SJ, Nakamura R, Diamond DJ. Real-time assessment of relapse risk based on the WT1 marker in leukemia and MDS patients after hematopoietic cell transplantation. Bone Marrow Transpl, 50(1):26-33, 2015. PMC4286541
  • Xu X, Hegazy WAH, Guo L, Gao X, Courtney AN, Kurbanov S, Liu D, Tian G, Manuel ER, Diamond DJ, Hensel M, and Metelitsa LS. Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system. Cancer Res. 74(21):6260-70, 2014. PMC4216746
  • Hardwick N, Chung V, Cristea M, Ellenhorn JDI, Diamond DJ. Overcoming Immuno-suppression to enhance a p53MVA vaccine: OncoImmunology. 3(10):e958949, 2014.  PMC4292557
  • Wussow F, Chiuppesi F, Martinez J, Campo J, Johnson E, Flechsig C, Newell M, Tran E, Ortiz J, La Rosa C, Herrmann A, Longmate J, Chakraborty R, Barry PA, Diamond DJ. Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer Complex. PLOS Pathog. 10(11):e1004524, 2014. PMC4239111
  • Hardwick N, Carrol M, Kaltcheva T, Qian D, Lim D, Leong L, Chu P, Kim J, Chao J, Fakih M, Yen Y, Espenschied J, Ellenhorn DI, Diamond DJ, Chung V. p53MVA therapy in patients with refractory gastrointestinal malignancies  elevates p53-specific CD8+ T cell responses. Clin Cancer Res. 20:4459-4470, 2014. PMC4155000
  • Gillis PA, Hernandez-Alvarado N, Gnanandarajah JS, Wussow F, Diamond DJ, Schleiss MR. Development of a novel, guinea pig-specific IFN-gamma ELISPOT assay and characterization of guinea pig CMV GP83-specific cellular immune responses following immunization with an MVA-vectored GP83 vaccine. Vaccine, 32(31):3963-3970, 2014.  PMC4279957
  • Nakamura R, La Rosa C, Tsai W, Behrendt C, Lacey S, Srivastava T, Seidel A, Senitzer D, Forman SJ and Diamond DJ. Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients. Transpl Immunol. 30, 128-135, 2014. PM:24582729
  • Gao C, Kozlowska A, Nechaev S, Li H, Hossain DMS, Zhang Q, Kowolik CM, Chu P, Swiderski P, Diamond DJ, Pal SK, Raubitschek A, Kortylewski M. TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiation therapy. Cancer Res. 73(24):7211-21, 2013. PMC3917779
  • Gil A, Shen S, Coley S, Gibson L, Diamond DJ, Wang S, Lu S. DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human CMV. Hum Vaccin Immunother. 9(10):2120-2132, 2013.  PMC3906396.
  • Manuel ER and Diamond DJ. Tumor growth control with IDO-silencing salmonella–     Reply. Cancer Res. 73(14):4592-4593, 2013. PMC3804125.
  • Israyelyan A, La Rosa C, Tsai W, Kaltcheva T, Srivastava T, Lo J, Aquino L, Li J, Kim Y, Palmer J, Senitzer D, Zaia JA, Rosenwald A, Forman SJ, Nakamura R, Diamond DJ. Detection and preliminary characterization of CD8+ T lymphocytes specific for Wilms’ tumor antigen in patients with non-Hodgkin lymphoma. Leukemia Lymphoma, 54(11):2490-2499, 2013. PMC3795970
  • Manuel ER and Diamond DJ. A road less traveled paved by IDO silencing: Harnessing neutrophils for anti-tumor activity. OncoImmunology, 2:3, e23322, 2013.  PMC3661160
  • Wussow F, Yue Y, Martinez J, Deere JD, Herrmann, A., Longmate, J., Barry PA, Diamond DJ. A Vaccine Based on the Rhesus Cytomegalovirus UL128 Complex Induces Broadly Neutralizing Antibodies in Rhesus Macaques. J Virol. 87(3):1322-1332, 2013.  PMC3554163
  • Blache CA, Manuel ER, Kaltcheva TI, Wong AN, Ellenhorn JDI, Blazar BR, and Diamond DJ. Systemic Delivery of Salmonella Typhimurium Transformed with IDO shRNA Enhances Intratumoral Vector Colonization and Suppresses Tumor Growth.  Cancer Res. 72:6447-6456, 2012. PMC3525777
  • Fan H, Zhang IY, Chen X, Zhang L, Wang H, Carvalho da Fonseca AC, Manuel ER, Diamond DJ, Raubitschek AA, and Badie B. Intracerebral CpG Immunotherapy with Carbon Nanotubes Abrogates Growth of Subcutaneous Melanomas in Mice. Clin Cancer Res. 18(20):5628-5638, 2012. PMC3483143
  • Assaf B, Mansfield K, Westmoreland S, Kaur A, Oxford K, Diamond DJ, and Barry P. Patterns of Acute Rhesus Cytomegalovirus (RhCMV) Infection Predict Long-Term RhCMV Infection. J Virol, 86: 6354-6357, 2012. PMC3372188
  • La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, Kwon P, J Drake, Williams B, Denison S, Broyer S, Couture L, Nakamura R, Kelsey MI, Krieg AM, Diamond DJ, and Zaia JA. Clinical Evaluation of Safety and Immunogenicity of PADRE-CMV and Tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis. 205:1294-1304, 2012. PMC3308906
  • La Rosa, C. and Diamond DJ. The immune response to human cytomegalovirus.  Future Virol. 7(3): 279-293, 2012. PMC3539762
  • Manuel ER, Blache CA, Ellenhorn JDI, Diamond DJ. Surviving the Battle Against Immunosuppression: Author’s View. OncoImmunology. 1(2): 240-241, 2012. PMC3377007
  • Song GY, Srivastava T, Ishizaki H, Lacey SF, Diamond DJ, and Ellenhorn JDI. Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild Type Human p53 Induces Specific Anti-tumor CTL Expansion. Cancer Invest. 29:501-510, 2011. PMC3260009
  • Oxford KL, Strelow L, Yue Y, Chang WL, Schmidt KA, Diamond DJ, Barry PA. Open reading frames carried on UL/b' are implicated in shedding and horizontal transmission of rhesus cytomegalovirus in rhesus monkeys. J Virol. (10):5105-14, 2011. PMC3126184
  • La Rosa C, Limaye A, Krishnan A, Blumstein G, Longmate J, Diamond DJ. Primary response against CMV during antiviral prophylaxis  with valganciclovir in solid organ transplant recipients. Transpl Int. 24(9):920-931, 2011.  PMC3514504
  • Lacey SF, La Rosa C, Kaltcheva T, Srivastava T, Seidel A, Zhou W, Rawal R, Hagen K, Longmate J, Andersson HA, Bhatia R, Pullarkat V, Forman SJ, Cooper LJN, Molldrem J, and Diamond DJ. Characterization of immunological properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. Blood, 118(8):2159-2169, 2011. PMC3162352
  • Manuel ER, Blache CA, Paquette R, Kaltcheva TI, Ellenhorn JDI, Hensel M, Metelitsa L, and  Diamond DJ. Enhancement of Cancer Vaccine Therapy by Systemic Delivery of a Tumor Targeting Salmonella-based STAT3 shRNA Suppresses the Growth of Established Melanoma Tumors. Cancer Res. 71:4183-4191, 2011. PMC3117077
  • Zhao D, Alizadeh D, Zhang L, Liu W, Farrukh O, Manuel E, Diamond DJ, Badie B. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin Cancer Res. 17 (4):771-782, 2011.  PMC3041854
  • Ishizaki H, Manuel E, Song G-Y, Srivastava T, Diamond DJ, Ellenhorn JDI. Modified vaccinia Ankara (MVA) expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immun. 60(1):99 -109, 2011.  PMC3289969
  • Abel K, Martinez J, Yue Y, Lacey SF, Wang Z, Strelow L., Dasgupta A, Li Z, Schmidt  KA, Oxford KL, Assaf B, Longmate JA, Diamond DJ, and Barry PA. Vaccine-Induced Control of Viral Shedding following Rhesus Cytomegalovirus Challenge in Rhesus Macaques. J Virol.  85(6):2878-2890, 2011. PMC3067943
  • Seidel A, Smith D, Yung E, Aquino L, Srivastava T, Pullarkat V, Spielberger R, Forman SJ and Diamond DJ. CD154 expression correlates with neutralizing antibody titer against Influenza post- vaccination in stem cell transplant patients and healthy adults. Biol Blood Marrow Tr, 17(4):524-533, 2011. PMC2933414
  • Ishizaki H, Song G-Y, Srivastava S, Carroll KD, Shahabi V, Diamond DJ, Ellenhorn JDI. Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression. J Immunother, 33(6):609-617, 2010. PMC3523364
  • Manuel ER, Wang Z, Li Z, La Rosa C, Zhou W, Diamond DJ. Intergenic region 3 of MVA is a stable site for insert gene expression and facilitates potent antigen-specific immune responses. Virology, 403(2):155-162, 2010. PMC2879446
  • Althoff KN, Anastos K, Nelson KE, Celentano DD, Sharp GB, Greenblatt RM, French AL, Diamond DJ, Holman S, Young M, Gange SJ. Predictors of reported influenza vaccination in HIV-infected women in the United States. Preventive Medicine, 50(5-6):223-2299, 2010. PMC2883293
  • Krishnan A, Zhou W, Lacey SF, Limaye AP, Diamond DJ and La Rosa C. PD-1 and IL-10 in liver transplant recipients at high risk for late cytomegalovirus disease. Transpl Infect Dis. 12(4):363-70, 2010. PMC2950160
  • Wang Z, Zhou W, La Rosa C, Martinez J, Li Q, Srivastava T, Rawal R, Britt WJ, Diamond DJ. Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine. 28(6):1547-1557, 2010. PMC2821965
  • Zhou W, Longmate J, Lacey SF, Palmer JM, Gallez-Hawkins G, Thao L, Spielberger R, Nakamura R, Forman SJ, Zaia JA, and Diamond DJ. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood. 113 (25):6465-6476, 2009. PMC2710937
  • Gallez-Hawkins GM, Thao L, Palmer J, Dagis A, Li X, Franck AE, Tegtmeier B,  Lacey SF, Diamond DJ, Forman SJ, and Zaia JA. Increased programmed death-1 molecule expression in CMV disease and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tr. 15(7):872-880, 2009. PMC2763574
  • Zaia JA, Sun JY, Gallez-Hawkins GM, Thao L, Oki A, Lacey S, Dagis A, Palmer J, Diamond DJ, Forman SJ, Senitzer D. The effect of single and combined activating KIR genotypes on CMV infection and immunity after hematopoietic cell transplant.  Biol Blood Marrow Tr. 15:315-325, 2009. PMC2770248
  • Li J, Srivastava T, Rawal R, Manuel E, Isbell D, Tsark W, La Rosa C, Wang Z, Li Z, Barry PA, Hagen K, Longmate J, Diamond DJ. Mamu-A01/K(b) transgenic and MHC Class I knockout mice as a tool for HIV vaccine development. Virology.
  • Krishnan A, Wang Z, Srivastava T, Rawal R, Manchanda P, Diamond DJ, and La Rosa C. A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models.  Immunology Letters. 120:108-116, 2008. PMC2577668
  • Wang Z, Zhou W, Srivastava T, La Rosa C, Mandarino A, Forman SJ, Zaia JA, Britt WJ, Diamond DJ. A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. Virology. 377(2): 379-390, 2008. PMC2504324
  • Yue Y, Wang Z, Abel K, Li J, Strelow L, Mandarino A, Eberhardt MK, Schmidt KA, Diamond DJ, Barry PA. Evaluation of recombinant modified vaccinia Ankara virus-based rhesus CMV vaccines in rhesus macaques. Med Microbiol Immunol. 197(2):117-123, 2008. PM:18196272
  • La Rosa C, Krishnan A, Longmate J, Martinez J, Manchanda P, Lacey SF, Limaye AP and Diamond DJ. PD-1 expression in liver transplant recipients as a prognostic indicator of CMV disease. J Infect.Dis. 197 (1):25-33, 2008. PM:18171281
  • Zhou W, Sharma M, Martinez J, Srivastava T, Diamond DJ, Knowles WA, Lacey SF. Functional characterization of BK virus-specific cytotoxic CD4+ T-cells in seropositive healthy adults. Viral Immunol. 20(3):379-388, 2007. PM:17931108
  • Margolin K, Synold, TW, Lara P, Frankel P, Lacey SF, Quinn DI, Baratta T, Dutcher JP, Xi B, Diamond DJ, and Gandara DR. Oblimersen and a-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin, 133(10):705-711, 2007. PM: 17508219
  • La Rosa C, Limaye AP, Krishnan A, Longmate J and Diamond DJ. Longitudinal assessment of CMV-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis, 195:633-644, 2007. Editorial Commentary by Boeckh and Riddell in same issue (195:615-617). PM:17262704
  • Song G-Y, Gibson G, Haq W, Huang EC, Srivastava T, Hollstein M, Daftarian P, Wang Z, Diamond DJ, and Ellenhorn J. An MVA vaccine overcomes tolerance to human p53 in mouse and humans. Cancer Immunol Immun. 56(8): 1193-1205, 2007. PM:17219151
  • Wang Z, La Rosa C, Li Z, Ly H, Krishnan A, Martinez J, Britt WJ, and Diamond DJ. Vaccine Properties of a Novel Marker Gene-Free Recombinant Modified Vaccinia Ankara (MVA) Expressing Immunodominant CMV Antigens pp65 and IE1.  Vaccine, 25(6):1132-1141, 2006. PMC1852509
  • Lacey SF, La Rosa C, Zhou W, Sharma MC, Martinez J, Krishnan A, Gallez-Hawkins G, Thao L, Longmate J, Spielberger R, Forman SJ, Limaye A, Zaia JA, and Diamond DJ. Functional Comparison of T-Cells Recognizing CMV pp65 and IE1 Polypeptides in HSCT and SOT Recipients. J Infect Dis 194: 1410-1421, 2006. PM:17054071
  • Sharma MC, Zhou W, Martinez J, Krymskaya L, Srivastava T, Haq W,  Diamond DJ, and Lacey SF. Cross-reactive CTL recognizing two HLA-A*02-restricted epitopes within the BK virus and JC virus VP1 polypeptides are frequent in immunocompetent individuals. Virology.  350 (1):128-136, 2006. PM:16600320
  • La Rosa C, Wang Z, Lacey SF, Lalimarmo MM, Krishnan A, Longmate J, Diamond DJ. In Vitro Expansion of Polyclonal T cells Subsets for Adoptive Immunotherapy by Recombinant Modified Vaccinia Ankara. Exp Hematol. 34(4):497-507, 2006. PM:16569596
  • Wang Z, La Rosa C, Lacey SF, Ly H, Lalimarmo M, Britt W, Diamond DJ.  Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J Clin Virol, 35(3):324-331, 2006. PM:16388983
  • Khanna, R and Diamond, DJ. Human cytomegalovirus vaccine: Time to look for alternative options. Trends Mol Med. 12(1):26-33, 2006. PM:16337831
  • Gallez-Hawkins G, Thao L, Lacey SF, Martinez J, Xiuli L, Franck AE, Lomeli NA, Longmate J, Diamond DJ, Speilberger R, Forman SJ, Zaia JA. CMV Immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplantation irrespective of detectable CMV infection. Biol Blood Marrow Tr, 11(11):890-902, 2005. PM:16275592
  • Krymskaya L, Sharma M, Martinez J, Haq W, Huang EC, Limay AP, Diamond DJ, Lacey SF. Cross reactivity of T-lymphocytes recognizing a human cellular epitope within BK and JC virus VP1 polypeptides. J.Virol. 79 (17):11170-11178, 2005.  PMC1193623
  • Lau SK, Yuan-Yuan C, Wen-Gang C, Diamond DJ, Mamelak AN, Zaia JA, Weiss LM. Lack of association of CMV with human brain tumors. Modern Pathol. 18: 838-843, 2005. PM:15578071
  • Daftarian P, Sharan R, Ali S, Haq W, Longmate J, Termini J, and Diamond DJ. Novel Conjugates of Epitope Fusion Peptides with CpG-ODN Display Enhanced Immunogenicity and HIV Recognition. Vaccine. 23(26): 3453-68, 2005. PM:15837369
  • Lacey SF, Martinez J, Gallez-Hawkins G, Thao L, Longmate J, Haq W, Spielberger R, Forman SJ, Zaia JA, and Diamond DJ. Simultaneous Reconstitution of Multiple CMV-Specific CD8+ T–cell Populations with Divergent Functionality In Hematopoietic Stem Cell Transplant Recipients. J  Infect Dis. 191 (6):977-84, 2005. PM:15717275
  • Villacres MC, Literat O, DeGiacomo M, Du W, LaRosa C, Diamond DJ and Kovacs A. Reduced type 1 and type 2 cytokines in anti-viral memory T helper function among women co-infected with HIV and HCV. J Clin Immunol. 25(2):134-41, 2005. PMC3127261
  • La Rosa C, Wang Z, Lacey SF, Markel SF, Sharma MS, Martinez J, Lalimarmo MM and Diamond DJ. Characterization of Host Immunity to CMV-pp150 (UL32). Hum Immunol. 66 (2):115-125, 2005. PM:15694996
  • Gallez-Hawkins G, Li X, Franck AE, Thao L, Lacey S, Diamond DJ, and Zaia JA.  DNA and low titer, helper-free, recombinant AAV for CMV prime boost vaccination induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice. Vaccine. 23 (6):819-826, 2004. PM:15542207
  • Daftarian P, Ali S, Song G-Y, Diamond DJ, and Ellenhorn JDI.  Two Distinct Pathways of Immuno-modulation Improve Potency of p53 Immunization in Rejecting Established Tumors.  Cancer Res. 64 (15):5407-5414, 2004. PM:15289349
  • Wang Z, La Rosa C, Mekhoubad S, Lacey S, Villacres M, Markel S, Ellenhorn JDI, Siliciano RF, Buck C, Britt WJ and Diamond DJ. Attenuated Poxviruses Generate Clinically Relevant Frequencies of CMV-Specific T cells. Blood. 104(3):847-856, 2004. PM:15090456
  • Lacey S, Diamond DJ, and Zaia JA. Assessment of Cellular Immunity to Human Cytomegalovirus in Recipients of Allogeneic Stem Cell Transplants. Biol Blood Marrow Tr. 10(7):433-447, 2004. PM:15205665
  • Wang Z, La Rosa C, Maas R, Ly H, Brewer J, Mekhoubad S, Daftarian P, Longmate J, Britt WJ, and Diamond DJ. Recombinant MVA expressing a soluble form of Glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of CMV. J Virol. 78(8): 3965-3976, 2004. PMC374285
  • Villacres MC, Longmate J, Auge C, and Diamond DJ. Predominant type 1 CMV-Specific memory T-helper response in humans: evidence for gender differences in cytokine secretion. Hum Immunol. 65 (5):476-485, 2004. PM:15172447
  • Gibson L, Piccinini B, Lilleri D, Revello MG, Wang Z, Markel S, Diamond DJ, Luzuriaga K. Human Cytomegalovirus Proteins pp65 and IE1 are Common Targets for CD8+ T cell Responses in Children with Congenital or Postnatal Human CMV infection.  J Immunol. 172(4): 2256-2264, 2004. PM:14764694
  • Daftarian P, Ali S, Sharan R, Lacey SF, La Rosa C, Longmate J, Buck C, Siliciano RF, and Diamond DJ. Immunization with TH-CTL Fusion Peptide and CpG DNA in Transgenic HLA A2 Mice Induces Recognition of HIV-infected T cells and Clears a Vaccinia Virus Challenge. J Immunol. 171(8): 4028-39, 2003. PM:14530323
  • Villacres MC, Lacey SF, Auge C, Longmate J, Leedom JM, and Diamond DJ. Relevance of Peptide Avidity to the TCR for CMV-specific ex vivo CD8 T Cell Cytotoxicity.  J Infect Dis. 188(6): 908-918, 2003. PM:12964124
  • Lacey SF, Villacres MC, La Rosa C, Wang Z, Longmate J, Martinez J, Brewer JC,  Mekhoubad S, Maas R, Forman SJ, Zaia JA and Diamond DJ. Relative dominance of HLA-B*07-Restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol. 64: 440-452, 2003. PM:12651070
  • Espenschied J, Lamont J, Longmate J, Pendas S, Wang Z, Diamond DJ, and Ellenhorn JDI. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in a established murine tumor model. J Immunol. 170: 3401-3407, 2003. PM:12626601
  • Epel M, Ellenhorn JDI, Diamond DJ, and Reiter Y.  A Functional Recombinant Single-Chain T Cell Receptor Fragment Capable of Selectively Targeting Antigen-Presenting Cells.  Cancer Immunol Immunother. 51: 565-573, 2002. PM:12384808
  • La Rosa C, Wang Z, Brewer JC, Lacey SF, Villacres MC, Sharan R, Krishnan R, Crooks M, Markel S, Maas R, and Diamond DJ. Pre-clinical Development of an Adjuvant-Free Peptide Vaccine with Activity Against CMV pp65 in HLA Transgenic Mice. Blood.100(10):3681-3689, 2002. PM:12393676
  • Lacey SF, Gallez-Hawkins G, Crooks M, Spielberger R, Forman SJ, Zaia JA and Diamond DJ. Characterization of Cytotoxic Function of CMV-pp65-Specific CD8+ T-lymphocytes Identified by HLA Tetramers in Recipients and Donors of Stem Cell Transplants. Transplantation. 74 (5):722-732, 2002. PM:12352893
  • (1):16-28, 2009. PM:19249807 PMC2667874
  • G. Gallez-Hawkins, N. A. Lomeli, X. Li, Yao Z-Q, C. La Rosa, D. J. Diamond, and John A. Zaia. Kinase-deficient CMVpp65 triggers a CMVpp65-specific T-cell immune response in HLA-A*0201 transgenic mice after DNA immunization. Scand J Immunol. 55: 592-598, 2002. PM:12028562
  • BenMohamed, L., Denis, M., Auge, C., Primus, J., and Diamond D.J. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology. 106:113-121, 2002. PMC1782698
  • MC Villacres, S Lacey, C La Rosa, R Krishnan, C Auge, J. Longmate, J. Zaia, JM Leedom and D.J. Diamond.  HIV patients receiving HAART maintain activated CD8+ cell subsets as a strong adaptive immune response to CMV. J Infect Dis.184:256-267,2001. PM:11443550
  • Zaia JA, Gallez-Hawkins G, Liu X, Yao Z-Q , Lomeli N, Molinder K, La Rosa C, and Diamond DJ. Infrequent Occurrence of Natural Mutations in the pp65 495-503 Epitope Sequence Presented by the HLA A*0201 Allele among Human Cytomegalovirus Isolates. J Virol. 75(5): 2472-2474, 2001. PMC114832
  • Yao Z-Q, Gallez-Hawkins G, Lomeli NA, Li X,  Molinder KM, Diamond DJ, and Zaia JA. Site-directed mutation in a conserved kinase domain of human CMV-pp65 with preservation of cytotoxic T lymphocyte targeting. Vaccine. 19 (13-14):1628-1635, 2001. PM:11166885
  • La Rosa C, Krishnan R, Markel S, Schneck JP, Houghten R, Pinilla C, and  Diamond DJ. Enhanced Immune Activity of CTL Epitope Analogues Derived from Positional Scanning Synthetic Combinatorial Libraries. Blood. 97(6):1776-1786, 2001. PM:11238120
  • Longmate J, York J, La Rosa C, Krishnan R, Zhang M, Senitzer D, and  Diamond DJ. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics. 52 (3-4):165-173, 2001. PM:11220618
  • Zaia JA, Sissons P, Riddell S, and Diamond DJ. Status of CMV prevention and treatment in 2000. In Hematology 2000, pp 339-356, 2000. PM:11701550
  • BenMohamed L, Krishnan R, Auge C, Low L, Primus J, and Diamond DJ. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. Hum Immunol. 61(8):764-779, 2000. PM:10980387
  • Liu X, Peralta E, Ellenhorn J and Diamond DJ. Targeting of Human p53-       overexpessing Tumor Cells by an HLA  A*0201-restricted Murine T-Cell Receptor Expressed in Jurkat T cells. Cancer Res. 60:693-701, 2000. PM:10676655
  • Peralta E, McCarty TM,  Doerr A, Jones PA, Markl I, Diamond DJ, and Ellenhorn JDI. Immunotherapy of bladder cancer by targeting p53. J Urology. 162(5):1806-11, 1999. PM:10524939
  • Schwarz RE, McCarty TM, Peralta EA, Diamond DJ, and Ellenhorn JDI. An orthotopic in vivo model of human pancreatic cancer. Surgery, 126 (3): 562-567, 1999. PM:10486610
  • McCarty TM, Yu Z, Liu X, Diamond DJ, and Ellenhorn JD.  An HLA-restricted p53 specific immune response from HLA transgenic p53 knockout mice. Ann Surg Oncol. 5(1):93-99, 1998.  PM:9524714
  • McCarty TM, Liu X, Sun J, Peralta EA, Diamond DJ, and  Ellenhorn JDI: Targeting p53  for adoptive T Cell immunotherapy. Cancer Res. 58: 2601-2605, 1998. PM:9635585
  • McCarty TM, Liu X, Schwarz RE, Diamond DJ, and Ellenhorn JDI. Targeting  p53 for adoptive T cell immunotherapy. Owen H. Wangensteen Surgical Forum.  48,783‑785, 1997.
  • Diamond DJ, York J, Sun J, Wright C, and Forman SJ. Development of an candidate HLA A*0201 restricted peptide-based vaccine against human CMV infection. Blood (Rapid Communication), 90: 1751-1767, 1997. PM:9292508
  • Yu Z, Liu X, McCarty TM, Diamond DJ, Ellenhorn JDI: The use of transgenic mice to generate p53 specific and HLA restricted cytolytic T cells (CTL). J Surg Res. 69: 337-343, 1997. PM:9224403
  • Krangel MS, Buchwalder A, York J, and Diamond DJ.  Lipid anchored and soluble forms of TCR molecules. In: Oksenberg, J. R. (ed). The Human Antigen T Cell Receptor: Selected Protocols and Applications. Georgetown, TX: R. G. Landes  Company 1997, pp 546-631.
  • Liu X, Chesnokova V, Forman SJ and Diamond DJ. Methods for determining         expression and oligoclonality of TCRs in GVHD lesions from allogeneic BMT recipients.  In:Oksenberg, J. R. (ed). The Human Antigen T Cell Receptor: Selected Protocols and Applications. Georgetown, TX: R. G. Landes Company 1997, pp 432-459.
  • Ellenhorn JDI, Yu Z, Diamond DJ. Generation of p53 specific and HLA restricted cytolytic T lymphocytes using recombinant vaccinia virus and HLA transgenic mice. Owen H. Wangensteen Surgical Forum.  47: 503‑505, 1996.
  • Liu X, Chesnokova V, Forman SJ and Diamond DJ. Molecular analysis of T cell receptor repertoire in bone marrow transplant recipients: evidence for oligoclonal T cell expansion in GVHD lesions. Blood. 87: 3032-3044, 1996. PM:8639927
  • Diamond DJ, Chang KL, Jenkins KA, and Forman SJ. Immunohistochemical  analysis of   T cell phenotypes in patients with graft versus host disease following allogeneic bone marrow transplantation. Transplantation. 59: 1436-1444, 1995. PM:7770932
  • Buchwalder A, Krangel M, Hao P, Diamond DJ. Immunochemical and molecular analysis of antigen binding to lipid anchored and soluble forms of an MHC independent human alpha/beta T cell receptor. 31: 857-872 ,1994. PM:8047075
  • Symer DE, Dintzis RZ, Diamond DJ, and Dintzis HM. Inhibition or of human T cell receptor transfectants by defined soluble antigen arrays. J Exp Med. 176: 1421-1430, 1992. PMC2119418
  • Brown D, Kondo K, and Diamond DJ. Characterization of nuclear protein binding to the Interferon-g promoter in quiescent and activated human T cells. Eur J Immunol. 22: 2419-2428, 1992. PM:1516629
  • Diamond DJ, Siliciano RF, Szalay P, Symer P, Hao P, Reinherz EL, Dintzis HM. MHC independent T cell receptor-antigen interaction: Functional analysis using fluorescein derivatives. J Exp.Med. 174:229-241, 1991. PMC2118876
  • Brown D, Nelson FB, Reinherz EL, and Diamond DJ. The human Interferon-gene contains an inducible promoter that can be transactivated by Tax I and II. Eur J Immunol. 21: 1879-1885, 1991. PM:1831129
  • Diamond DJ, Nelson FB, and Reinherz EL. Lineage‑Specific Expression of a T‑Cell Receptor Variable Gene Promoter Controlled By Upstream Sequences.  J Exp Med. 169:1213‑1231, 1989. PMC2189238
  • Diamond DJ, Clayton LK, Sayre PH, and Reinherz EL.  Exon‑intron organization and sequence comparison of human and murine T11 (CD2) genes. P Natl Acad Sci U.S.A. 85:1615‑1619, 1988. PMC279824
  • Clayton LK, Ramachandran H, Pravtcheva D, Chen Y, Diamond DJ, and Reinherz EL. The gene for T11 (CD2) maps to chromosome 1 in humans and to chromosome 3 in Mice. J Immunol. 140:361-367, 1988. PM:2896210
  • Hayday AC, Diamond DJ, Tanigawa G, Heilig JS, Folsom V, Saito H, and Tonegawa S. Unusual organization and diversity of T cell receptor alpha chain genes. Nature (London) 316, 828-830, 1985. PM:2993907
  • Diamond DJ and Goodman HM. Regulation of growth hormone mRNA synthesis by dexamethasone and triiodothyronine: Transcriptional rate and mRNA stability changes in pituitary tumor cells. J Mol Biol. 181: 41-62, 1985.
  • Fukata J, Diamond DJ, and Martin JB. Effects of rat growth hormone releasing factor and somatostatin on the release and synthesis of rGH in dispersed pituitary cells.  Endocrinology. 117: 457-467, 1985. PM:2862007
  • Moore DD, Walker MD, Diamond DJ, Conkling MA, and Goodman HM. Structure, expression and evolution of growth hormone genes. Recent Prog Hor Res, 38: 197-225, 1982. PM:6289392
  • Goodman HM, Berg P, Clark S, Cordell B, Diamond DJ, Nguyen-Huu C, Kan YW, and Lebo RV. Structure, evolution and expression of mammalian insulin genes. In: Schmitt, F.O., Bird, S.J., and Bloom, F.E. (eds.), Molecular Genetic Neuroscience, pp.103-115. New York: Raven Press (1982).
  • Cordell B, Diamond DJ, Smith S, Punter J., Schone H.H., and Goodman, H.M. Disproportionate expression of the two non-allelic rat insulin genes of a pancreatic tumor is due to translational control. Cell. 31: 531-542, 1982. PM:6297771
  • Lehrach H, Diamond DJ, Wozney JM, and Boedtker H. RNA molecular weight determination by gel electrophoresis under denaturing conditions: A critical re-examination. Biochemistry-US. 16: 4743-4750, 1977. PM:911786Diamond DJ Studies at the scute locus of Drosophila melanogaster. Seccan News Magazine. 4: 1-4 (1973).
Back To Top